LON:INDV Indivior (INDV) Share Price, News & Analysis GBX 736 -39.00 (-5.03%) (As of 11:51 AM ET) Add Compare Share Share Today's Range 720.50▼ 769.5050-Day Range 756.50▼ 1,21152-Week Range 653▼ 1,877.20Volume134.35 million shsAverage Volume2.13 million shsMarket Capitalization£969.68 millionP/E RatioN/ADividend Yield2.04%Price TargetGBX 1,500 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Indivior alerts: Email Address Indivior MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside103.8% UpsideGBX 1,500 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.33Based on 8 Articles This WeekInsider TradingAcquiring Shares£1.50 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.48 out of 5 stars 3.5 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has only been the subject of 1 research reports in the past 90 days.Read more about Indivior's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for INDV. Previous Next 1.7 Dividend Strength Dividend LeadershipIndivior is a leading dividend payer. It pays a dividend yield of 4.48%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthIndivior does not have a long track record of dividend growth.Read more about Indivior's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDV. Previous Next 1.8 News and Social Media Coverage News SentimentIndivior has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Indivior this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for INDV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Indivior to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have bought more of their company's stock than they have sold. Specifically, they have bought £14,989.40 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 3.36% of the stock of Indivior is held by insiders.Percentage Held by Institutions88.81% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Indivior's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is -931.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is -931.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Indivior, their PEG ratio cannot be calculated. Previous Next See Top Rated MarketRank™ Stocks Here Ad Market JARTesla of the Skies? SRFM Takes FlightRemember when Tesla disrupted the auto industry? Buckle up, because Surf Air Mobility (NYSE:SRFM) could have the potential to do the same for aviation. The $75+ billion regional air mobility market is taking shape now. Don't let this opportunity fly by!Discover SRFM's Potential Today About Indivior Stock (LON:INDV)Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesSeptember 10 at 8:35 AM | markets.businessinsider.comMaintaining Buy Rating: Indivior’s Growth Prospects and Undervaluation Despite Near-Term ChallengesSeptember 8 at 11:22 PM | markets.businessinsider.comROSEN, LEADING INVESTOR COUNSEL, Encourages Indivior PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action - INDVSeptember 10, 2024 | Behind the Markets (Ad)[NOTICE] Your Download Link BelowIf you still haven't downloaded our brand new report: "The Last Retirement Stock You'll Ever Need"...September 6, 2024 | americanbankingnews.comDeutsche Bank Aktiengesellschaft Reaffirms "Buy" Rating for Indivior (LON:INDV)September 6, 2024 | americanbankingnews.comIndivior (LON:INDV) Stock Price Down 7.9%September 5, 2024 | markets.businessinsider.comDeutsche Bank Sticks to Their Buy Rating for Indivior (INDV)September 5, 2024 | benzinga.comFrench Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise OptionSeptember 2, 2024 | stockhouse.comA Case Has Been Filed Against Indivior PLC For Breaching Securities Regulations And Shareholders Are Urged To Contact The Schall Law FirmSeptember 10, 2024 | Behind the Markets (Ad)[NOTICE] Your Download Link BelowIf you still haven't downloaded our brand new report: "The Last Retirement Stock You'll Ever Need"...September 1, 2024 | markets.businessinsider.comROSEN, A TOP-RANKED LAW FIRM, Encourages Indivior PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action - INDVAugust 19, 2024 | stockhouse.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Indivior PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action - INDVAugust 16, 2024 | finance.yahoo.comHypera S.A. (HM6A.F)August 9, 2024 | stockhouse.comIndivior PLC Investor Notice: Robbins LLP Reminds Stockholders of the INDV Class Action LawsuitJuly 27, 2024 | bizjournals.comRichmond-area company reaches $86M opioid settlement with Va., other statesJuly 27, 2024 | msn.comIndivior inks $86M multistate settlement over opioid crisisJuly 25, 2024 | markets.businessinsider.comIndivior’s Strong Q2 Performance and Positive Outlook Prompt Buy RatingJuly 25, 2024 | seekingalpha.comIndivior PLC (INDV) Q2 2024 Earnings Call TranscriptJuly 25, 2024 | marketwatch.comIndivior Shares Jump on Increased Revenue, $100M Share BuybackSee More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolLON:INDV CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees1,000Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,500 High Stock Price TargetGBX 1,500 Low Stock Price TargetGBX 1,500 Potential Upside/Downside+103.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.79) Trailing P/E RatioN/A Forward P/E Ratio694.34 P/E Growth-5.57Net Income£-141,000,000.00 Net Margins-12.29% Pretax MarginN/A Return on Equity12.20% Return on Assets2.37% Debt Debt-to-Equity Ratio2,790.00 Current Ratio0.85 Quick Ratio1.52 Sales & Book Value Annual Sales£1.15 billion Price / Sales0.84 Cash FlowGBX 274.62 per share Price / Cash Flow2.68 Book ValueGBX (90) per share Price / Book-8.18Miscellaneous Outstanding Shares131,750,000Free FloatN/AMarket Cap£969.68 million OptionableNot Optionable Beta0.17 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Executive DirectorMr. Ryan PreblickCFO & Executive DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVice President of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 52)Chief Legal Officer Mr. Jon FogleChief Human Resources OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMr. Vishal KaliaSVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy OfficerMore ExecutivesKey CompetitorsSophos Group plc (SOPH.L)LON:SOPHHUTCHMEDLON:HCMGraingerLON:GRIIthaca EnergyLON:ITHStandard Life UK Smaller Companies TrustLON:SLSView All CompetitorsInsidersJo Le CouilliardBought 1,490 shares on 7/26/2024Total: £1.50 M ($1,006.00/share)Mark CrossleySold 10,549 sharesTotal: £17.06 M ($1,617.00/share)Mark CrossleySold 15,444 sharesTotal: £25.39 M ($1,644.00/share)Graham HetheringtonBought 1,743 shares on 12/20/2023Total: £2.07 M ($1,189.00/share)Graham HetheringtonBought 2,650 shares on 11/20/2023Total: £3.58 M ($1,350.00/share)View All Insider Transactions INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at GBX 1,185 at the beginning of 2024. Since then, INDV stock has decreased by 37.9% and is now trading at GBX 736. View the best growth stocks for 2024 here. How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK) and Bodycote (BOY). This page (LON:INDV) was last updated on 9/10/2024 by MarketBeat.com Staff From Our PartnersTesla of the Skies? SRFM Takes FlightRemember when Tesla disrupted the auto industry? Buckle up, because Surf Air Mobility (NYSE:SRFM) could have t...Market JAR | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredExposed: The Plot to Destroy AmericaIs Your Family Prepared for Kamala’s America? The coup has already begun. Kamala Harris is just one step aw...Banyan Hill Publishing | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.